Home LiteratureArticle Details
PMID: 19689234 Published · ppublish English Journal Article Multicenter Study Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.

Baseline MRI predictors of conversion from MCI to probable AD in the ADNI cohort.

Current Alzheimer research ·Vol. 6 ·No. 4 ·2009-08-00 ·Pages 347-61

Risacher SL, Saykin AJ, West JD, Shen L, Firpi HA, McDonald BC, Alzheimer's Disease Neuroimaging Initiative ADNI

Abstract

The Alzheimer's Disease Neuroimaging Initiative (ADNI) is a multi-center study assessing neuroimaging in diagnosis and longitudinal monitoring. Amnestic Mild Cognitive Impairment (MCI) often represents a prodromal form of dementia, conferring a 10-15% annual risk of converting to probable AD. We analyzed baseline 1.5T MRI scans in 693 participants from the ADNI cohort divided into four groups by baseline diagnosis and one year MCI to probable AD conversion status to identify neuroimaging phenotypes associated with MCI and AD and potential predictive markers of imminent conversion. MP-RAGE scans were analyzed using publicly available voxel-based morphometry (VBM) and automated parcellation methods. Measures included global and hippocampal grey matter (GM) density, hippocampal and amygdalar volumes, and cortical thickness values from entorhinal cortex and other temporal and parietal lobe regions. The overall pattern of structural MRI changes in MCI (n=339) and AD (n=148) compared to healthy controls (HC, n=206) was similar to prior findings in smaller samples. MCI-Converters (n=62) demonstrated a very similar pattern of atrophic changes to the AD group up to a year before meeting clinical criteria for AD. Finally, a comparison of effect sizes for contrasts between the MCI-Converters and MCI-Stable (n=277) groups on MRI metrics indicated that degree of neurodegeneration of medial temporal structures was the best antecedent MRI marker of imminent conversion, with decreased hippocampal volume (left > right) being the most robust. Validation of imaging biomarkers is important as they can help enrich clinical trials of disease modifying agents by identifying individuals at highest risk for progression to AD.

MeSH Terms
Aged Aged, 80 and over Alzheimer Disease/diagnosis,pathology Analysis of Variance Atrophy Brain Mapping Cerebral Cortex/pathology Cognition Disorders/diagnosis,pathology Disease Progression Female Hippocampus/pathology Humans Image Interpretation, Computer-Assisted Image Processing, Computer-Assisted Magnetic Resonance Imaging Male Middle Aged Multivariate Analysis Neuropsychological Tests Organ Size Predictive Value of Tests
Authors & Affiliations
7 authors, click to expand affiliations / ORCID
Risacher Shannon L
IU Center for Neuroimaging, Division of Imaging Sciences, Department of Radiology, Indiana University School of Medicine, 950 W Walnut St, R2 E124, Indianapolis, IN 46202, USA.
Saykin Andrew J
West John D
Shen Li
Firpi Hiram A
McDonald Brenna C
Alzheimer's Disease Neuroimaging Initiative (ADNI)
References (83)
83 references, click to expand
  1. Voxel-based morphometry--the methods.
    Neuroimage. 2000 Jun;11(6 Pt 1):805-21 PMID: 10860804
  2. Disease-modifying approaches to Alzheimer's disease: challenges and opportunities-Lessons from donepezil therapy.
    Alzheimers Dement. 2008 Jan;4(1 Suppl 1):S109-18 PMID: 18631986
  3. Baseline and longitudinal patterns of brain atrophy in MCI patients, and their use in prediction of short-term conversion to AD: results from ADNI.
    Neuroimage. 2009 Feb 15;44(4):1415-22 PMID: 19027862
  4. 3D comparison of hippocampal atrophy in amnestic mild cognitive impairment and Alzheimer's disease.
    Brain. 2006 Nov;129(Pt 11):2867-73 PMID: 17018552
  5. Validation of the NPI-Q, a brief clinical form of the Neuropsychiatric Inventory.
    J Neuropsychiatry Clin Neurosci. 2000 Spring;12(2):233-9 PMID: 11001602
  6. Vitamin E and donepezil for the treatment of mild cognitive impairment.
    N Engl J Med. 2005 Jun 9;352(23):2379-88 PMID: 15829527
  7. Combining early markers strongly predicts conversion from mild cognitive impairment to Alzheimer's disease.
    Biol Psychiatry. 2008 Nov 15;64(10):871-9 PMID: 18723162
  8. Rate of medial temporal lobe atrophy in typical aging and Alzheimer's disease.
    Neurology. 1998 Oct;51(4):993-9 PMID: 9781519
  9. Tensor-based morphometry as a neuroimaging biomarker for Alzheimer's disease: an MRI study of 676 AD, MCI, and normal subjects.
    Neuroimage. 2008 Nov 15;43(3):458-69 PMID: 18691658
  10. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician.
    J Psychiatr Res. 1975 Nov;12(3):189-98 PMID: 1202204
  11. Measurement of functional activities in older adults in the community.
    J Gerontol. 1982 May;37(3):323-9 PMID: 7069156
  12. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer's disease.
    Neurology. 1989 Sep;39(9):1159-65 PMID: 2771064
  13. Use of structural magnetic resonance imaging to predict who will get Alzheimer's disease.
    Ann Neurol. 2000 Apr;47(4):430-9 PMID: 10762153
  14. Conversion of mild cognitive impairment to Alzheimer disease predicted by hippocampal atrophy maps.
    Arch Neurol. 2006 May;63(5):693-9 PMID: 16682538
  15. Different regional patterns of cortical thinning in Alzheimer's disease and frontotemporal dementia.
    Brain. 2007 Apr;130(Pt 4):1159-66 PMID: 17353226
  16. Medial temporal atrophy on MRI in normal aging and very mild Alzheimer's disease.
    Neurology. 1997 Sep;49(3):786-94 PMID: 9305341
  17. Mild cognitive impairment as a diagnostic entity.
    J Intern Med. 2004 Sep;256(3):183-94 PMID: 15324362
  18. Mini-Mental State Examination (MMSE).
    Psychopharmacol Bull. 1988;24(4):689-92 PMID: 3249771
  19. A voxel based morphometry study on mild cognitive impairment.
    J Neurol Neurosurg Psychiatry. 2005 Jan;76(1):11-4 PMID: 15607988
  20. MRI predictors of risk of incident Alzheimer disease: a longitudinal study.
    Neurology. 2005 May 10;64(9):1520-4 PMID: 15883311
  21. Validation of a fully automated 3D hippocampal segmentation method using subjects with Alzheimer's disease mild cognitive impairment, and elderly controls.
    Neuroimage. 2008 Oct 15;43(1):59-68 PMID: 18675918
  22. The magnitude of dementia occurrence in the world.
    Alzheimer Dis Assoc Disord. 2003 Apr-Jun;17(2):63-7 PMID: 12794381
  23. MRI as a biomarker of disease progression in a therapeutic trial of milameline for AD.
    Neurology. 2003 Jan 28;60(2):253-60 PMID: 12552040
  24. Mild cognitive impairment: clinical characterization and outcome.
    Arch Neurol. 1999 Mar;56(3):303-8 PMID: 10190820
  25. Small baseline volume of left hippocampus is associated with subsequent conversion of MCI into dementia: the Göteborg MCI study.
    J Neurol Sci. 2008 Sep 15;272(1-2):48-59 PMID: 18571674
  26. 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment.
    Brain. 2008 Mar;131(Pt 3):665-80 PMID: 18263627
  27. Hippocampal and entorhinal atrophy in mild cognitive impairment: prediction of Alzheimer disease.
    Neurology. 2007 Mar 13;68(11):828-36 PMID: 17353470
  28. VBM anticipates the rate of progression of Alzheimer disease: a 3-year longitudinal study.
    Neurology. 2008 Jun 3;70(23):2201-11 PMID: 18448872
  29. Rates of hippocampal atrophy correlate with change in clinical status in aging and AD.
    Neurology. 2000 Aug 22;55(4):484-89 PMID: 10953178
  30. Spatial patterns of brain atrophy in MCI patients, identified via high-dimensional pattern classification, predict subsequent cognitive decline.
    Neuroimage. 2008 Feb 15;39(4):1731-43 PMID: 18053747
  31. Ways toward an early diagnosis in Alzheimer's disease: the Alzheimer's Disease Neuroimaging Initiative (ADNI).
    Alzheimers Dement. 2005 Jul;1(1):55-66 PMID: 17476317
  32. Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects.
    Brain. 2009 May;132(Pt 5):1310-23 PMID: 19042931
  33. A voxel-based morphometry study of temporal lobe gray matter reductions in Alzheimer's disease.
    Neurobiol Aging. 2003 Mar-Apr;24(2):221-31 PMID: 12498956
  34. What's in a name: voxel-based morphometric analyses of MRI and naming difficulty in Alzheimer's disease, frontotemporal dementia and corticobasal degeneration.
    Brain. 2004 Mar;127(Pt 3):628-49 PMID: 14761903
  35. Brain atrophy rates predict subsequent clinical conversion in normal elderly and amnestic MCI.
    Neurology. 2005 Oct 25;65(8):1227-31 PMID: 16247049
  36. Detection of grey matter loss in mild Alzheimer's disease with voxel based morphometry.
    J Neurol Neurosurg Psychiatry. 2002 Dec;73(6):657-64 PMID: 12438466
  37. Using voxel-based morphometry to map the structural changes associated with rapid conversion in MCI: a longitudinal MRI study.
    Neuroimage. 2005 Oct 1;27(4):934-46 PMID: 15979341
  38. Medial temporal lobe atrophy on MRI predicts dementia in patients with mild cognitive impairment.
    Neurology. 2004 Jul 13;63(1):94-100 PMID: 15249617
  39. Older adults with cognitive complaints show brain atrophy similar to that of amnestic MCI.
    Neurology. 2006 Sep 12;67(5):834-42 PMID: 16966547
  40. Hippocampal volume and shape analysis in an older adult population.
    Clin Neuropsychol. 2007 Jan;21(1):130-45 PMID: 17366281
  41. Global and local gray matter loss in mild cognitive impairment and Alzheimer's disease.
    Neuroimage. 2004 Oct;23(2):708-16 PMID: 15488420
  42. The Alzheimer's Disease Neuroimaging Initiative (ADNI): MRI methods.
    J Magn Reson Imaging. 2008 Apr;27(4):685-91 PMID: 18302232
  43. FreeSurfer-initiated fully-automated subcortical brain segmentation in MRI using Large Deformation Diffeomorphic Metric Mapping.
    Neuroimage. 2008 Jul 1;41(3):735-46 PMID: 18455931
  44. Cortical surface-based analysis. I. Segmentation and surface reconstruction.
    Neuroimage. 1999 Feb;9(2):179-94 PMID: 9931268
  45. A voxel-based morphometric study of ageing in 465 normal adult human brains.
    Neuroimage. 2001 Jul;14(1 Pt 1):21-36 PMID: 11525331
  46. The contribution of voxel-based morphometry in staging patients with mild cognitive impairment.
    Neurology. 2006 Aug 8;67(3):453-60 PMID: 16894107
  47. 3D maps from multiple MRI illustrate changing atrophy patterns as subjects progress from mild cognitive impairment to Alzheimer's disease.
    Brain. 2007 Jul;130(Pt 7):1777-86 PMID: 17533169
  48. The Alzheimer's disease neuroimaging initiative.
    Neuroimaging Clin N Am. 2005 Nov;15(4):869-77, xi-xii PMID: 16443497
  49. CSF biomarkers and medial temporal lobe atrophy predict dementia in mild cognitive impairment.
    Neurobiol Aging. 2007 Jul;28(7):1070-4 PMID: 16782233
  50. Measuring the thickness of the human cerebral cortex from magnetic resonance images.
    Proc Natl Acad Sci U S A. 2000 Sep 26;97(20):11050-5 PMID: 10984517
  51. Automatic differentiation of anatomical patterns in the human brain: validation with studies of degenerative dementias.
    Neuroimage. 2002 Sep;17(1):29-46 PMID: 12482066
  52. MRI patterns of atrophy associated with progression to AD in amnestic mild cognitive impairment.
    Neurology. 2008 Feb 12;70(7):512-20 PMID: 17898323
  53. Multivariate deformation-based analysis of brain atrophy to predict Alzheimer's disease in mild cognitive impairment.
    Neuroimage. 2007 Oct 15;38(1):13-24 PMID: 17827035
  54. Structural MRI discriminates individuals with Mild Cognitive Impairment from age-matched controls: a combined neuropsychological and voxel based morphometry study.
    Alzheimers Dement. 2006 Oct;2(4):296-302 PMID: 19020671
  55. MRI of hippocampus and entorhinal cortex in mild cognitive impairment: a follow-up study.
    Neurobiol Aging. 2008 Jan;29(1):31-8 PMID: 17097769
  56. Volumetric MRI and cognitive measures in Alzheimer disease : comparison of markers of progression.
    J Neurol. 2008 Apr;255(4):567-74 PMID: 18274807
  57. MRI-derived entorhinal volume is a good predictor of conversion from MCI to AD.
    Neurobiol Aging. 2004 Oct;25(9):1197-203 PMID: 15312965
  58. Amnestic mild cognitive impairment: structural MR imaging findings predictive of conversion to Alzheimer disease.
    AJNR Am J Neuroradiol. 2008 May;29(5):944-9 PMID: 18296551
  59. Understanding diseases by mouse click: the promise and potential of computational approaches in Systems Biology.
    Clin Exp Immunol. 2007 Sep;149(3):424-9 PMID: 17666096
  60. Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment.
    Neurology. 1999 Apr 22;52(7):1397-403 PMID: 10227624
  61. Efficacy of donepezil in mild cognitive impairment: a randomized placebo-controlled trial.
    Neurology. 2004 Aug 24;63(4):651-7 PMID: 15326237
  62. Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: a systematic review and meta-analysis.
    Clin Interv Aging. 2008;3(2):211-25 PMID: 18686744
  63. Discrimination between Alzheimer disease, mild cognitive impairment, and normal aging by using automated segmentation of the hippocampus.
    Radiology. 2008 Jul;248(1):194-201 PMID: 18458242
  64. Prediction of Alzheimer's disease in mild cognitive impairment: a prospective study in Taiwan.
    Neurobiol Aging. 2006 Dec;27(12):1797-806 PMID: 16321457
  65. MRI-derived entorhinal and hippocampal atrophy in incipient and very mild Alzheimer's disease.
    Neurobiol Aging. 2001 Sep-Oct;22(5):747-54 PMID: 11705634
  66. Predictors of conversion to dementia of probable Alzheimer type in patients with mild cognitive impairment.
    Curr Alzheimer Res. 2006 Apr;3(2):161-70 PMID: 16611017
  67. Medial temporal lobe atrophy predicts Alzheimer's disease in patients with minor cognitive impairment.
    J Neurol Neurosurg Psychiatry. 2002 Apr;72(4):491-7 PMID: 11909909
  68. Global prevalence of dementia: a Delphi consensus study.
    Lancet. 2005 Dec 17;366(9503):2112-7 PMID: 16360788
  69. A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment.
    Neuropsychopharmacology. 2005 Jun;30(6):1204-15 PMID: 15742005
  70. Pathological verification of ischemic score in differentiation of dementias.
    Ann Neurol. 1980 May;7(5):486-8 PMID: 7396427
  71. A comprehensive study of gray matter loss in patients with Alzheimer's disease using optimized voxel-based morphometry.
    Neuroimage. 2003 Apr;18(4):895-907 PMID: 12725765
  72. Comparison of different MRI brain atrophy rate measures with clinical disease progression in AD.
    Neurology. 2004 Feb 24;62(4):591-600 PMID: 14981176
  73. Whole brain segmentation: automated labeling of neuroanatomical structures in the human brain.
    Neuron. 2002 Jan 31;33(3):341-55 PMID: 11832223
  74. Apolipoprotein E epsilon 4 allele is associated with increased atrophy in progressive mild cognitive impairment: a voxel-based morphometric study.
    Neurodegener Dis. 2008;5(3-4):186-9 PMID: 18322386
  75. Imaging and CSF studies in the preclinical diagnosis of Alzheimer's disease.
    Ann N Y Acad Sci. 2007 Feb;1097:114-45 PMID: 17413016
  76. Analysis of brain and cerebrospinal fluid volumes with MR imaging: impact on PET data correction for atrophy. Part II. Aging and Alzheimer dementia.
    Radiology. 1991 Jan;178(1):123-30 PMID: 1984290
  77. The Clinical Dementia Rating (CDR): current version and scoring rules.
    Neurology. 1993 Nov;43(11):2412-4 PMID: 8232972
  78. In vivo mapping of gray matter loss with voxel-based morphometry in mild Alzheimer's disease.
    Neuroimage. 2001 Aug;14(2):298-309 PMID: 11467904
  79. Voxel-based morphometry to discriminate early Alzheimer's disease from controls.
    Neurosci Lett. 2005 Jul 15;382(3):269-74 PMID: 15925102
  80. Cortical surface-based analysis. II: Inflation, flattening, and a surface-based coordinate system.
    Neuroimage. 1999 Feb;9(2):195-207 PMID: 9931269
  81. Voxel-based morphometry to detect brain atrophy in progressive mild cognitive impairment.
    Neuroimage. 2007 Oct 1;37(4):1122-31 PMID: 17683950
  82. MRI and CSF studies in the early diagnosis of Alzheimer's disease.
    J Intern Med. 2004 Sep;256(3):205-23 PMID: 15324364
  83. Volumetric MRI vs clinical predictors of Alzheimer disease in mild cognitive impairment.
    Neurology. 2008 Jan 15;70(3):191-9 PMID: 18195264
Article Info
Journal
Current Alzheimer research
Abbr.
Curr Alzheimer Res
ISSN
1875-5828
Published
2009-08-00
Pages
347-61
Language
English
Region
United Arab Emirates
NLM ID
101208441
PMCID
PMC2764863
Subset
IM
Grants
NIA NIH HHS · P30 AG10133 · United States
NIA NIH HHS · U19 AG010483 · United States
NIA NIH HHS · U01 AG024904 · United States
NIA NIH HHS · R01 AG19771 · United States
NIBIB NIH HHS · R03 EB008674 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]